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  . . . and the blind, wise blood bankers said, “These an-
tibodies are high-titered and have low avidity, they are red 
cell, white cell antibodies, they are clinically insignificant, 
are not reactive with enzyme-treated red cells, and can be 
absorbed with white cells!” Then the chorus of other blind, 
wise blood bankers said, “NO, THEY ARE NOT!”
 based on memories of discussions about these antibodies 
back in the 1970s and the fable of the elephant and blind wise 
men—r. mougey
 It was a delight, an honor, and also a little intimidating 
to be asked to write a review of the Chido/Rodgers blood 
group system, especially considering that the last author to 
pen a review for Immunohematology on this subject was 
Carolyn M. Giles, the author of so many important publi-
cations on Chido and Rodgers. Moreover, the recent dis-
coveries about Chido and Rodgers have moved well beyond 
the field of blood group serology to an understanding of the 
functional protein and genetics at a molecular level.
 My delight was in the opportunity to revisit my early 
days in performing antibody identification and think again 
about the challenges that blood bankers faced then in work-
ing with a group of antibodies that no one could agree about. 
Chido and Rodgers were usually lumped in with this group, 
which in light of current knowledge is quite understandable. 
As I recall even the pronunciation for Chido was a matter of 
some dispute, with adherents claiming that “Cheedo” with 
a short i vowel, not Chido with a long i sound, was correct. 
It occurred to me that this review should cover a historical 
perspective, which might be helpful to those blood bankers 
whose testing experience is derived from the newer meth-
ods of gel column or solid-phase technology and who might 
be wondering what all the fuss was about. The review will 
then cover the current understanding of the serology, func-
tion, and biochemistry, and then the genetics of C4 and the 
Chido/Rodgers blood group system. The nomenclature for 
the complement system is very confusing even for blood 
bankers who deal routinely with a nomenclature for a blood 
group that is just as confusing.
Historical Perspective
 In the beginning there was confusion and chaos. Dur-
ing the 1960s and ’70s, the process for antibody identifica-
tion was usually a straightforward and consistent exercise 
with good consensus between individual technical staff and 
among laboratories, except there was this group of anti-
bodies that “would not cooperate.” In the reference labo-
ratory where I worked, we called them “the grubbies,” but 
we were too frustrated by working with them to go much 
further than that. The usual experience was to spend an 
inordinate amount of time performing every possible test, 
which led only to excluding what the antibody could not 
be. Then when additional samples were obtained to con-
tinue the investigation, it was not uncommon to find that 
tests that had appeared to be nonreactive were now reactive 
with the new antibody sample or with a freshly collected 
sample of the test cell.  It took me a while to recognize that 
with these antibodies, if you wanted to test for specificity 
by typing the patient’s RBCs or testing known antigen posi-
tive or negative RBCs, it was best to use the freshest RBCs. 
If you wanted to find compatible blood, older donor units 
were more likely to be nonreactive. That is, it was gener-
ally agreed that there were some patients whose antibod-
ies could not be identified as any of the then known anti-
bodies and whose reactivity was so weak there was a lot of 
disagreement as to which test RBCs were truly nonreactive. 
This made it very difficult to define and describe the true 
characteristics of the antigens and the antibodies and show 
that the antigens were expressed on the RBC as an inherited 
trait. This variability was partly a result of testing methods, 
which relied heavily on a multiphasic set of incubation tem-
peratures and the use of a polyclonal antiglobulin reagent. 
In that period, blood bankers went to great lengths to de-
tect and identify room temperature–reactive antibodies as 
well as antibodies active at 37°C. The use of fresh serum for 
testing was usually considered essential, with the end result 
that blood bankers were pretty good at detecting clinically 
significant antibodies but even better at finding clinically 
insignificant antibodies. Blood bankers got lots of prac-
tice at identifying these clinically insignificant antibodies, 
and neutralizing them with human breast milk, avian egg 
albumin, hydatid cyst fluid, saliva, and human and guinea 
pig urine. The grubbies defied these efforts, and there was 
much discussion, some of it acrimonious, on how patients 
with these antibodies ought to be managed. The term high 
titer, low avidity was preferred by many if only for its ac-
ronym HTLA, even though everyone knew that these anti-
bodies were not always of high titer or of low avidity. When 
such weak antibodies were shown to be of high titer, it de-
fied logic that the antibody should show such poor avidity. 
Obviously, the fault could lie with the antigen, either its ori-
entation or its number of sites, or some other property not 
yet realized. Again, there was a contradiction in the patient 
making a high-titered antibody if there was so little antigen 
to stimulate the production of antibodies. The first glimmer 
of understanding in these contradictory findings was the re-
ports on anti-Chido.
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Discovery and Serology of Chido/Rodgers
 The Chido antibody was first studied in a patient in 
1962, and in a collaborative effort between laboratories in 
Minneapolis, Minnesota, and London, United Kingdom, it 
was found to be reactive with nearly all cells tested but was 
consistently nonreactive with the RBCs of a London panel 
donor. Six additional examples were found, and the anti-
body was named Chido after one of the patients and the 
combined results were published by Harris et al. in 1967.1 
Their title is as good a description of the grubbies as any, “A 
nebulous antibody responsible for crossmatching difficul-
ties.” The authors reported that the antibodies could not be 
inhibited by saliva, urine, or hydatid cyst fluid.
 During this time, there was much speculation about 
these grubby antibodies being RBC-WBC antibodies, that 
came from some successful experiments using WBCs to ad-
sorb these antibodies.2 This whole issue of mistaken identity 
was very understandable because of the not uncommon an-
tibody problem known as anti-Bgs. Bg antibodies had been 
shown to be hemagglutinins with anti-HLA specificity, and 
the Bg antigens were thought to be remnants of those HLA 
antigens expressed on the RBC before the loss of its nucle-
us. Because Bgs were antigens of lower frequency, it would 
have been so tidy to have them be the antithetical allele to 
Chido as the variable strength of reactivity seemed so simi-
lar. Eventually it was realized that the “grubby” antibodies 
had nothing to do with WBC antigens. There may have been 
sufficient residual plasma in the WBC preparations used to 
adsorb the antibodies, now known to be capable of inhib-
iting anti-Chido, to lead to this mistaken conclusion. The 
speculation that the Chido antigen was a WBC antigen did 
lead to studies for possible linkage with HLA, an important 
advance as linkage studies had shown no association with 
any other blood groups.
 Many additional examples of anti-Chido were found, 
and it was thought that these antibodies did not seem to 
cause obvious destruction of Chido-positive donor RBCs. 
The work of Middleton and Crookston3 published in 1972 
provided the clue that led to recognizing the true nature of 
the blood group. In an attempt to enhance the reactivity 
of the anti-Chido they were studying, inert human plasma 
was added to the tests; a common practice of the time was 
to add a source of protein to enhance antibody binding for 
antihuman globulin (AHG) reactions when using polyspe-
cific AHG. The authors recognized that when the antibody 
reactivity disappeared after the addition of plasma the 
Chido antigen must also be in plasma. They then found 
that performing Chido antigen typings using the plasma of 
the person being typed in a neutralization test was a much 
more reliable way to type individuals for the Chido antigen 
than testing their RBCs. They also noted that weak Chido 
antigen reactivity on an individual’s RBCs did not appear 
to correlate with the amount of antigen in that person’s 
plasma. The ability to neutralize anti-Chido was also a use-
ful tool for antibody identification, especially in sera with 
multiple antibodies. This was the first way in which Chido 
was distinguished from the other so-called HTLA specifici-
ties Knops, Csa, and Yka, although some workers continued 
to think of anti-Yka as also showing some inhibition with 
plasma.4
 At this point, the Chido antigen was thought to be a 
plasma antigen that was adsorbed onto the RBC much like 
the Lewis antigens. Once accurate, reproducible antigen 
typings were possible, family studies on the inheritance of 
the Chido gene led to the discovery that Chido was linked 
to HLA.5 This potential relationship to HLA prolonged the 
use of the term RBC-WBC antibodies, but the recognition of 
HLA linkage to Chido led to the studies to see whether other 
genes known to be linked to HLA would also show linkage 
to Chido.
 The description of anti-Rodgers, a second antibody re-
active with an RBC antigen of high prevalence  that could be 
neutralized by plasma, followed in 1976.6 The antibody was 
formed by a transfused patient whose RBCs were Chido-
positive who also made an anti-E. The anti-Rga (as anti-Rg 
was referred to at that time) gave weak to 4+ reactions with 
E– RBCs (not your typical low-avidity antibody). Using 
plasma neutralization tests, Longster and Giles found that 
3.1 percent of donors could not inhibit the antibody, i.e., 
were Rodgers-negative, although they found some donors 
who were only partial inhibitors. Nordhagen et al.7 were 
also able to demonstrate partial inhibition of anti-Chido by 
the plasma of Chido-positive subjects, and Giles8 showed 
that partial inhibition was an inherited trait. These findings 
would explain conflicting results in tests on Chido/Rodgers 
antibodies among laboratories if a single source of plasma 
was used in inhibition tests. The common practice now is to 
use a pool of inert plasmas when attempting to determine 
whether an unknown antibody is neutralizable by human 
plasma.
 Rodgers was also shown to be linked to HLA in two 
studies in 1976 that set the stage for the discovery of the 
relationship of Chido and Rodgers to the C4 protein.9,10 In 
1978, O’Neill et al.11 showed that Chido and Rodgers are an-
tigenic determinants expressed on the C4 complement pro-
tein. Then Tilley et al.12 showed that the Chido and Rodgers 
determinants are on the C4d fragment of the C4 molecule. 
The small amount of C4d normally found on the RBC mem-
brane is the limiting factor that explains the low avidity of 
anti-Chido or anti-Rodgers. In fact, if large amounts of C4d 
are bound to the RBC under low ionic conditions, anti-Ch 
or anti-Rg can be turned into a strongly reactive, direct ag-
glutinin.13 The puzzle of incomplete or partial inhibition of 
the antibodies is caused by the extreme polymorphism of 
the C4 genes with multiple alleles that cause variations in 
the Ch or Rg determinants.
 All this progress made Chido and Rodgers antibodies 
easier to recognize with the exception of Chido-positive 
variant individuals who have made anti-Chido to the part 
of the Chido antigen that they lack.14 The further serologic 
complexities of Chido/Rodgers specificity will be discussed 
in the section on genetics.
Chido/Rodgers review
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 The inexorable unraveling of the puzzle of the true na-
ture of the blood group Chido/Rodgers is an excellent ex-
ample of the importance of recognizing anomalous findings 
in the study of antibodies that most blood bankers wished 
could just be ignored! The final refutation of the term HTLA 
came from the revelation that the Knops, McCoy, Swain-
Langley, and York blood group sera recognize antigens that 
are carried on the RBC complement receptor CR1.15,16 How-
ever, this finding seemed to have brought a level of kinship 
to these antibodies with Chido and Rodgers that must have 
been satisfying to those who wanted to believe that Chido, 
Knops, etc. must be related. Again the low avidity of most 
Knops antibodies is probably related to the low copy num-
ber of the individual’s CR1 receptor. It also seems likely that 
these blood groups will be forever linked in the literature as 
those HTLAs when they are studied by aspiring blood bankers.
Clinical Significance of Chido/Rodgers
 It is well documented that many patients with Chido/
Rodgers antibodies have been safely transfused with “ran-
dom” RBC units, but there are also reports of significant re-
actions to plasma or platelet transfusions in patients with 
anti-Chido or -Rodgers,17,18 a cautionary incident remind-
ing blood bankers not to ignore the potential significance of 
an antibody based on specificity alone. Strupp et al.19 also 
pointed out the danger in assuming that antibodies that 
appear to be of low avidity may be safely ignored without 
further investigation. They reported 4 patients with sickle 
cell disease for whom the provision of compatible blood and 
benefit of transfusion were delayed because Dombrock an-
tibodies were not initially recognized and identified. How-
ever, there is a need to determine the best way to detect and 
identify these antibodies without incurring unnecessary 
delays and expense to the patient, but how much testing is 
enough? It sometimes seems that when we had the time, 
resources, and people to detect and identify these antibod-
ies, we did not have a clue what they were. Now we know all 
about them and do not have the time, people, or resources 
to do much with them. In this area as with so many other 
blood group issues, perhaps molecular methods will identify 
good patient practices, and with the use of microarray tech-
nology, definitive answers to some of these thorny issues 
of cost versus benefit will be found. Until that time, when 
patients with known anti-Chido or anti-Rodgers require 
RBC transfusions, antibody detection, identification, and 
crossmatching methods should include plasma-neutraliza-
tion studies. After all, these patients are known antibody 
formers. If transfusion of plasma components is required, 
there should be some consideration given to the possible 
effects on the patient of receiving a large volume of plasma, 
such as the formation of precipitating immune complexes 
or anaphalaxis.17,18 Finally, the presence of antibodies to C4 
proteins may indicate a potential disease association such 
as is seen with the patients who have anti-Ch and anti-Rg 
and are C4-deficient.
 The story of Chido and Rodgers blood groups has moved 
well beyond the “crossmatching difficulties,” and there is 
now a wealth of new material that shows the C4 genes and 
proteins to be a fascinating model for the evolution of the 
genes for critical biologic processes that can both protect 
and attack their host organism.
Structure and Function of the C4 Protein
 The C4 protein expressing the Chido or Rodgers 
epitopes occurs in two isoforms, called C4A for acidic (for-
merly C4F) and C4B for basic (formerly C4S).20 Awdeh and 
Alper20 proposed the change from F for fast and S for slow 
to conform with the then new International System for Hu-
man Gene nomenclature and because in their experiments 
sialic acid was removed from plasma proteins before elec-
trophoresis, resulting in distinct but different bands from 
those in the experiments of O’Neill et al.,11 which were the 
first to link the Chido/Rodgers antigen to C4 proteins. C4A 
proteins usually carry the Rodgers antigens and C4B, the 
Chido antigens, although a number of haplotypes have been 
discovered in which these associations were switched.21,22
 C4A or C4B protein is expressed as a single-chain pre-
cursor of 1744 amino acid residues, and the C4A or C4B 
amino acid sequences are nearly identical (99%) except near 
residues 1000 to 1200.23 The amino acid substitutions that 
occur at residues 1101 to 1106 distinguish C4A from C4B. 
Single-nucleotide polymorphisms (SNP) are also found in 
the region that distinguishes the alleles of C4A from each 
other and from C4B and its alleles. The Chido and Rodgers 
antigens are thought to differ by both amino acid substitu-
tion as well as conformational binding sites.24
 After translation, the pro-C4 protein is cleaved into al-
pha, beta, and gamma polypeptide chains that are linked 
by disulfide bonds.25 However, incomplete processing ac-
tually leads to multiple structural forms of the peptide be-
ing secreted in the plasma.26 The activated complement 
component C1 initiates cleavage of 77 amino acids from 
the N-terminus of the alpha chain, releasing C4a, and the 
remainder of the molecule C4b changes shape, exposing 
a thioester bond between the sulfhydryl group of Cys-991 
and the carbonyl group of Gln-994. This binding site that 
is exposed on activation will allow the formation of either 
a covalent ester or an amide linkage.27,28 Activated C4B is 
more efficient than C4A at pathogen cell lysis because of its 
histidine residue at position 1106 and its serine residue at 
position 1102.29
 The liver is the primary site of C4 production, with 
smaller amounts produced by macrophages in other tis-
sues.30 There is a wide variation in the amount of C4 pro-
duced among individuals. The concentration of C4 in the 
plasma varies from 80 to 1000 µg/mL with variable con-
centrations of C4 isotypes.31 Moulds et al.32 found variation 
in patterns of C4 protein levels in individuals that showed 
either a complete absence of C4A or C4B, more C4A than 
C4B, more C4B than C4A, or equal amounts of both. There 
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is some correlation between C4 gene copy number varia-
tions and certain polymorphisms with the level of C4 pro-
tein produced, but the effect at the haplotype level can be 
lost in the diploid gene expression.33
 C4 can be activated via the classical pathway or the 
mannan-binding lectin pathway, although this may be a 
simplistic view as a recent paper demonstrated the poten-
tial for localized release of anaphylatoxins C3a and C4a by 
tryptase under certain conditions such as those found in the 
airways of asthmatics.34 Although it is simpler to consider 
organized pathways in which complement proteins perform 
their complex dance with the other parts of the innate and 
humoral immune response, it is likely that the protection 
or attack effect is far more chaotic and layered in multiple 
mechanisms that activate, block, or break down these pro-
teins (see discussion on disease association).
 In the classical pathway, C4 is processed by activated 
C1, which removes C4a anaphylatoxin from the alpha chain. 
C4a is a mediator of local inflammation and can induce the 
contraction of smooth muscle, increase vascular permeabil-
ity, and cause histamine release from mast and basophilic 
WBCs. C4a levels along with the anaphylatoxins C3a and 
C5a in plasma were shown to be elevated during normal 
pregnancy as an indication of the increased activation of the 
complement system, possibly as a protection against infec-
tion.35
 The remaining C4b fragment forms the enzymes C3 
convertase (C4bC2a) and C5 convertase (C3bC4bC2a). 
These enzymes catalyze the membrane attack proteins, 
which open a channel into the cell membrane. C4 binding 
protein (C4bp) is another plasma protein that regulates C4 
activity by blocking the formation of and promoting the 
decay of the classical pathway C3 convertase. Deficiency of 
C4bp would be expected to result in increased activation of 
C3 and complement activity in response to classical path-
way or lectin pathway activation by immune complex for-
mation, bacterial infections, apoptosis, and other triggering 
mechanisms.36
 Activated C4B (C4b-B) binds to its target rapidly but 
has a short half-life of less than 1 second and has greater 
hemolytic activity than C4A.28 Activated C4A (C4b-A) is 
10 times slower than C4B, but it forms amide bonds with 
amino group targets of immune complexes (IC) or protein 
antigens. C4B more efficiently forms ester bonds with car-
bohydrate antigens, resulting in better clearance of patho-
gens.
 Besides activation of the complement cascade via the 
classical or lectin pathways, the covalent binding of C4 to 
immunoglobulins and to IC enhances the solubilization of 
immune aggregates and the clearance of IC by binding to 
complement receptor on RBCs (CR-1). This IC binding on 
the RBC then acts as a shuttle and delivers the IC for phago-
cytosis by macrophages. Thus C4 plays multiple roles for 
both the innate and adaptive immune systems in vertebrate 
animals.37
 Part of this multiple role is the normal constant low 
level of activation of C3 via the classical pathway and the 
alternate pathway. In the classical pathway, it was thought 
that specific antigen binding by an antibody capable of ac-
tivating C1 would initiate the pathway, but Manderson et 
al.38 have shown that C3 is also being activated by C1–C4 in 
the absence of antibody-antigen complexes. They propose 
that although circulating constant low levels of IC could 
account for their findings, the continual circulation of the 
normal levels of IgG antibodies may form “spontaneous un-
stable Ig aggregates that would provide for a C3 tickover” as 
well. In their experiments, vascular stasis would encourage 
or initiate complement activation and would therefore be 
augmented at sites of inflammation. This would facilitate 
pathogen recognition by allowing the deposition of activated 
C3 fragments onto foreign surfaces (host cell surfaces with 
complement regulatory proteins would be unaffected).
 Thus the various polymorphisms of C4 affect the normal 
functioning of C4 and can be affected by the individual’s 
ability to produce suitable levels of C4 proteins. Deficiencies 
of C4 proteins whether acquired or inherited can increase 
the risk of severe viral and bacterial infections.33 How high 
levels of C4 may also contribute to the risk of diseases is 
just beginning to be understood (disease association will be 
discussed later).
Genetics of C4 and Chido/Rodgers
 The original notation of Cha and Rga implied the ex-
pectation that there would be additional antithetical al-
leles Chb and Rgb.1,6 However, it was soon realized that this 
blood group did not fit this pattern of inheritance. Chido, 
or Ch, and Rodgers, or Rg, are used to describe the cluster 
of determinants that are expressed on the C4A or C4B pro-
teins that can neutralize the antibodies formed by Chido- or 
Rodgers-negative individuals. Also individuals can type as 
positive with anti-Chido, but form anti-Chido to the Chido 
epitopes they lack. Currently nine antigens have been de-
scribed: six of high prevalence for Chido, two of high preva-
lence for Rodgers, and one of low prevalence, WH.24  Eight 
phenotypes for the CH/RG system, with their respective oc-
currences, are shown in Table 1 as the prevalence for the 
other antigen combinations has not been established (Table 
1).39 The polymorphisms for the Ch and Rg epitopes as well 









Ch:1,2,3 88.2 Rg:1,2 95.0
Ch:1,–2,3 4.9 Rg:1,–2 2.5
Ch:1,2,–3 3.1 Rg:–1,–2 2.5
Ch:–1,–2,–3 3.8
Ch:–1,2,–3 Rare
Ch:–1,2,3 (proposed but Rg:–1,2 (proposed but
Ch:–1,–2,3 may not exist) may not exist)
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as the polymorphisms for the electrophoretic behavior of 
the C4 protein confounded the early investigations on the 
inheritance of the C4 genes. No attempt is going to be made 
by this author to explain the reported phenotypic frequen-
cies of Ch and Rg antigens with the current understanding 
of the multiple copy number variation of the C4 gene.
 In early studies of the inheritance of Chido/Rodgers, 
it appeared that the genes must be encoded by two closely 
linked loci. The majority of persons were Chido-positive and 
Rodgers-positive. Approximately 1.7 percent of those stud-
ied were Chido-negative, Rodgers-positive, and 3 percent 
were Chido-positive, Rodgers-negative.3,6 After the linkage 
of Chido/Rodgers with HLA was established and the dis-
covery of C4 as the plasma protein carrier was made, family 
studies detecting both serologic allelic forms and electro-
phoretic alleles seemed initially to be in agreement with 
this model. It was proposed that null genes or duplicated 
genes for C4A or C4B led to lack of Rodgers or Chido.40
 As methods and antisera improved, numerous C4 al-
leles were discovered and the results of a workshop to 
define and standardize nomenclature were published in 
a joint paper by Mauff et al.41  They described 14 determi-
nants for the C4A gene and 17 for the C4B gene. Genes that 
express no C4A or C4B are designated with a *Q0 (mean-
ing quantity naught). In patients with complete deficiency 
of C4 (C4A*Q0/B*Q0), null alleles were thought to be at-
tributable to gene deletions or point mutations that cause 
a frameshift in the DNA sequence, leading to defective or 
no expression of the protein. One such example is a 2-bp 
insertion into the sequence for codon 1213 at exon 29 of the 
mutant C4A gene seen in both Caucasians and those of Af-
rican descent, but very rarely in those of Asian descent.42
 The origin of the complement system C3 and C4 pro-
teins predates the ability to make lymphocytes or antibod-
ies; the latter did not arise on the evolutionary scene until 
cartilaginous fish and sharks.43 Homology between C3 and 
C4 proteins indicates that the C4 gene may have evolved 
from C3 as a duplicated gene.44 The C4A gene is thought 
to have arisen by gene duplication and mutation from C4B 
because of its efficiency in facilitating the clearance of IC.28
 The C4A or C4B gene consists of 41 exons that in ad-
dition to encoding for an acidic or basic isotype can also 
exist as a long form of 20.6 kb or a short form of 14.2 kb.45 
The long form has an insertion of a human endogenous ret-
rovirus (HERV-K[C4]) into intron 9. The insertion of this 
retroviral material is thought to have occurred after dupli-
cation of the ancestral mammalian C4A gene but before the 
divergence of humans from the ancestors of other primates. 
The reading frames of the retrovirus are all closed, but 
there is still promoter activity and the HERV-K(C4) insert 
is thought to be able to modulate the expression of the C4 
gene.46 The long form was originally thought to be a C4A 
gene, but C4 genes can be C4A (long or short) or C4B (long 
or short). However, most C4A genes have the HERV-K(C4) 
insert and a greater proportion of C4B genes do not.
 The genes for C4A and C4B were shown to be located 
between HLA-DR and HLA-B loci on the short arm of chro-
mosome 6 along with C2 and factor B.40,47 C4A and C4B 
proteins are distinguished phenotypically by their migra-
tion patterns in electrophoretic gels and genetically by four 
nucleotide substitutions that encoded changes at residues 
1101 to 1106 where C4B encodes for LSPVIH and C4A en-
codes for PCPVLD at the protein level. C4A and C4B are 
also distinguished phenotypically by their expression of ei-
ther the Chido or the Rodgers antigen, which are the result 
of two amino acid substitutions at residues 1188 to 1191. 
The Ch1 epitope has ADLR and the Rg1 has VDLL. As data 
from family studies began to contradict a simple two-gene 
model, it was realized that a haplotype could have one, two, 
three, or four C4 genes and that the C4 genes were inher-
ited as part of a complex of genes.48 The two-gene theory had 
to give way to the current hypothesis of the inheritance of a 
haplotype modular gene complex that can vary by C4 copy 
number and is part of a larger gene complex in the MHC 
locus. This model explains both the qualitative and quanti-
tative nature of the C4 gene expression as regards epitopes, 
concentration of the C4 protein in the plasma, the frequency 
of certain haplotypes, and the association of C4 copy number 
variation with certain diseases. In fact, the C4 gene as part of 
the MHC complex can serve as an example of how the genes 
of an important biologic pathway evolve via the mechanics of 
meiosis and through the pressure of natural selection to con-
serve important genes and to maximize the utility of poly-
morphism potential. Gene duplication, translocation, single-
nucleotide polymorphisms, insertions, and deletions all have 
played a role in the plastic nature of the C4 gene.
 Both forms of C4 are highly homologous but either 
by SNP or by insertions or deletions display great qualita-
tive and quantitative diversity. The copy number variation 
comes from whether an individual has inherited haplotypes 
that have one, two, three, or four C4 genes.49 This gene clus-
ter occurs as a complex in the MHC locus near the centromere 
with flanking genes in the following order: first an intact 
RP gene (a serine/threonine kinase gene), an intact C4 
gene (either C4A or C4B), then an intact CYP21B gene (cy-
tochrome P450 21-hydroxylase gene), and an intact TNXB 
(tenascin-X protein). Approximately 17 percent of persons 
of Northern European ancestry have this haplotype, termed 
monomodular.50 In 83 percent of those of Northern Euro-
pean ancestry the C4 gene complex can contain one, two, 
or three duplicated gene clusters made of fragments or mu-
tations of the above flanking genes and an intact C4 gene. 
The duplicated gene complex, called RCCX, occurs between 
the C4 gene and the intact CYP21B gene and consists of a 
CYP21 (usually a mutated form) fused to a 4.9-kb fragment 
of TNXA fused to an RP2 0.91-kb fragment and an intact 
C4 (A or B and long or short). Depending on the number of 
RCCX modules duplicated, the complete C4 gene may be a 
monomodular (no RCCX duplication), bimodular, trimod-
ular, or quadrimodular form.
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 This modular gene duplication maximizes opportuni-
ties to conserve the C4 gene, whereas the opportunity for 
recombination allows greater diversity of polymorphisms. 
This great diversity should allow for a better response to 
pathogens but can create opportunities for unequal cross-
ing over during meiosis. Thus low or high copy number 
variations could be as important a risk factor for disease as 
the actual C4 polymorphism.
 C4 gene copy number studies done on healthy subjects 
of different ages indicate that those individuals with a low 
copy number for C4B may be less healthy or have a shorter 
lifespan than those having more than two copies of the C4B 
gene.51 These studies found that in healthy individuals old-
er than 50 years, there was a lower incidence of low copy 
number for the C4B gene when compared with the low copy 
number gene frequency in younger healthy individuals.
C4 and Disease Associations
 The association of C4 and a number of diseases has been 
a fruitful area of investigation, and at the genetic level, the 
frequency of C4 nulls or low copy variation shows a solid 
association with autoimmune disease, particularly systemic 
lupus erythematosus (SLE).52 Although the varying efficien-
cies of complement function that result from partial or com-
plete deficiency may have a profound effect on autoimmune 
susceptibility, above-average C4 protein levels may also in-
crease risk. Once a loss of self-tolerance occurs, having high 
levels of C4 may exacerbate the disease. Moreover, it cannot 
be overstated that association is not the same as causation. 
SLE can be thought of as a prototype for the intricacies of 
the interaction of C4 proteins both in the development of 
autoimmunity and in disease progression. Inheritance of a 
C4A*Q0 null gene shows a greater risk in Caucasian and 
African populations, but C4B*Q0 nulls are more frequent 
in SLE patients of Asian descent.53 SLE is a heterogeneous 
disease that is characterized by the presence of multiple au-
toantibody specificities that attack various tissues, result-
ing in tissue damage, which then presents more antigen to 
the host’s immune system. It has become increasingly clear 
that multiple genetic pathways are likely involved and that 
C4 polymorphism, especially copy number variation, can 
be a negative or a positive risk factor in the development 
of autoimmune diseases.54 This postulates that the function 
of C4 in the initiation of autoimmunity may be related to 
its role in presenting antigen to the host immune system, 
which is separate from the role of complement in the in-
flammatory process once autoantibodies have been formed. 
The current understanding of SLE genetics is that there are 
distinctions in severity, risk, and clinical manifestation that 
vary by ethnicity, geography, and sex with a greater preva-
lence in women and some non-Caucasian ethnic groups. 
Although genetics undoubtedly plays a role, SLE may also 
be associated with poverty and exposure to infectious dis-
eases.55,56
 Progress both in human genetics, particularly by 
genome-wide association studies, and in the understand-
ing of biologic pathways has led to the discovery of more 
than 20 different loci that show strong correlation to SLE.54 
Most of the genes identified are involved in three kinds of 
biologic processes. Minor variations in the genes encoding 
the proteins of IC processing, production of interferon, or 
signal transduction of immune cells can greatly increase the 
susceptibility of an individual to SLE. It is to be expected 
that more than one kind of trigger, such as pathogens, al-
lergens, or trauma, could then lead to disease.
 Inasmuch as a major function of the C4 protein is par-
ticipation in innate immunity, there is a strong 
association between deficiencies of C4 and recurrent in-
fections; although this is less frequent than other comple-
ment deficiencies.57 Table 2 lists other reported diseases 
and their possible association with C4 or complement.
 In their paper, Atkinson and Frank43 also warn that pa-
tients with complement C2- or C4-deficient states (either 
acquired or inherited) have backup complement activation 
mechanisms that must be considered in defining the role of 
complement and a disease. For example, the immune re-
sponse of specific antibody produced to a pathogen (antibody 
Table 2. Disease associations with low levels of C4/complement 
Date Disease Citation
2009 Schizophrenia Shi58
2008 Role of complement in schizophrenia Mayilyan59
2009 Chronic fatigue syndrome Sorenson60
2008 Autism and missing or nonfunctional C4B 
gene
Sweetehn61
2008 Alzheimer’s and increased C4 deposition Zhou62
2008 Increased morbidity/mortality associated 
with low expression of C4B, smokers, and 
stroke
Szilagyi63
2007 Cardiovascular disease, smokers, and low 
expression of C4B
Arason64
2006 C4 nulls and adult rhinosinusitis Seppänen65
2002 Systemic sclerosis Arason66
1996 Insulin-dependent diabetes and C4 poly-
morphisms
Lhotta67
1993 Graves’ disease Ratanachaiyavong68
1991 C4A deficiency and IgA nephropathy Wyatt69
1990 Felty’s syndrome Hillarby70
1989 Psoriasis Wyatt 71
1989 Rheumatoid arthritis Fielder72
1988 C4 allotypes in juvenile dermatomyositis Robb73
1987 C4B2 and primary biliary cirrhosis Briggs74
1984 Glomerulonephritis, Henoch-Schönlein 
purpura
McLean75
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excess) may be all that is needed to trigger more ancient 
pathways to perform cell lysis in the absence of sufficient 
complement proteins.
Summary
 The C4 protein plays an important role in maintaining 
health and, in some situations complicated by poor expres-
sion of the C4 protein, may lead to or exacerbate certain 
diseases. The blood groups Chido and Rodgers are epitopes 
on the C4 protein, and polymorphisms associated with 
these epitopes may lead to the formation of antibodies to 
the Chido or Rodgers antigens in transfused patients. Iden-
tification of anti-Ch or anti-Rg is still based on the antibody 
neutralization with plasma from Ch-positive or Rg-positive 
individuals and lack of reactivity with qualified Ch-negative 
or Rg-negative RBCs. These antibodies may be useful in 
genetic studies of C4 polymorphisms or, in the case of C4-
deficient patients, a signal of the potential for serious ill-
nesses. The recognition of the extreme polymorphism of the 
C4 gene and the gene complex RCCX should lead to more 
insights in the understanding of disease risk and potential 
treatment.
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